NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Dr. Glenn Gormley
Daiichi Sankyo Makes Two New Executive Appointments
Greg Barrett has been appointed as the new acting head of the Commercial Division of Daiichi Sankyo. He holds the new title of acting president, Daiichi Sankyo Administrative & Commercial Operations. In this role, Mr. Barrett is responsible for leading the Daiichi Sankyo U.S. Commercial Division, including marketing, sales, and supply chain operations in the U.S. organization. Mr. Barrett most recently held the position of VP, marketing and managed markets, at Daiichi Sankyo.
Glenn Gormley, M.D., Ph.D., has been named corporate president and chairman of Daiichi Sankyo. Dr. Gormley continues in his existing roles as president, Daiichi Sankyo Pharma Development, global head of research and Development, and senior executive officer of Daiichi Sankyo Co. Ltd.
Lilly Announces Emerging Market Promotion
Eli Lilly and Company has announced that Alfonso “Chito” Zulueta had been promoted to senior VP and president of the emerging markets business. Mr. Zulueta replaces Jacques Tapiero who has retired after 31 years of service to the company.
Mr. Zulueta has been president and general manager of Lilly Japan since 2008. In his new role, he is charged with leading the company’s efforts in many of the world’s fastest-growing markets in Asia, Latin America, Middle East and Africa, plus Russia and Turkey.
Alba Therapeutics Appoints CEO
Alba Therapeutics has appointed Wendy Perrow as its CEO. Her responsibilities include managing the company’s business, clinical, financial, licensing, and corporate development efforts. She previously served as president and chief operating officer and she has been a member of Alba’s executive management team since 2008.
Under her leadership, Alba Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases.
Dr. Vipin Garg
Neos Therapeutics Names CEO
Neos Therapeutics, a differentiated oral drug delivery company with a portfolio of proprietary technologies and a pipeline of innovative controlled release (CR) products, has named Vipin Garg, Ph.D., CEO.
Dr. Garg succeeds Neos Interim CEO, Alan Heller, who continues to serve as chairman.
Dr. Garg has more than 25 years of experience within the biotechnology and pharmaceutical industries in both technical and management positions. Before joining Neos Therapeutics, he served as president and CEO of Tranzyme Pharma.
Dr. Anna Schwendeman
ONL Announces Leadership Changes
ONL Therapeutics has named John Freshley CEO and Anna Schwendeman, Ph.D., VP of preclinical development. These appointments follow the loss of Co-Founder and former CEO Raili Kerppola to adrenal cancer in June 2013. Mr. Freshley most recently was chief business officer of Compendia Bioscience, a cancer genomics company that was acquired by Life Technologies in 2012.
Dr. Schwendeman has deep expertise in peptide drug manufacturing and regulatory affairs from her time at both Cerenis Therapeutics and Esperion Therapeutics.
Dr. Martin Sullivan
INC Research Appoints Executive Medical Director INC Research, a therapeutically focused global clinical research organization (CRO), has appointed Martin Sullivan, M.D., as executive medical director, cardiovascular medicine. Before joining the company, he worked as a research consultant specializing in noninvasive cardiology.
Dudnyk announces promotions and new hires
Kim Cosenza has been promoted to senior account executive at Dudnyk, which is a full-service healthcare advertising agency that supports biotech, biopharma, and medical device companies. This is her second promotion in just two years since she joined Dudnyk.
Mike Hawkins has been promoted to art supervisor. Mr. Hawkins joined the agency as a designer.
Ashley Hoffman joins the Dudnyk account team as account supervisor. She comes to the agency from Element Marketing Group.
Centron Expands Management Team
Centron has hired Shannyn Smith as executive VP, managing director. With more than a decade of experience in medical communications, Ms. Smith is charged with steering Centron’s medical education initiatives.
Neil de Crescenzo
Emdeon Appoints President and CEO
Emdeon, a provider of healthcare revenue and payment cycle management and clinical information exchange solutions, has appointed Neil de Crescenzo as president and CEO. Formerly, he was senior VP and general manager of Oracle’s global health sciences business.
Theravance Appoints Senior VP, Corporate and Business Development
Theravance, biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies, has named Jeff Jonker, senior VP, corporate and business development. Mr. Jonker’s responsibilities include managing the company’s business and corporate development efforts.
Mr. Jonker joins Theravance from Satori Pharmaceuticals, where he served as chief business officer.
Dr. Michael Kitt
Afferent Pharmaceuticals Names Chief Medical Officer
Michael Kitt, M.D., has been named to the newly created position of chief medical officer at Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company leading the development of first-in-class, small molecule compounds that target P2X3 receptors for the treatment of chronic pain, respiratory, and urological conditions.
Dr. Kitt has more than 30 years of experience in drug development with a proven record of success in running clinical trial programs and taking compounds through to NDA approval. He most recently served as senior VP, clinical research and regulatory affairs and chief medical officer at Portola Pharmaceuticals, where he led the planning and initiation of an international Phase III clinical program for the company’s lead product candidate.
Dr. Frank Hsu
Immune Design Appoints VP, Head of Oncology
Immune Design, a biotech company focused on the development of novel immune-based therapies for cancer and other human diseases, has appointed Frank J. Hsu, M.D., as its VP, Head of Oncology.
Dr. Hsu is charged with overseeing the translational medicine and clinical development of the company’s immunotherapeutic oncology programs.
Dr. Hsu recently served as chief medical officer for Zyngenia, where he was responsible for strategic planning and clinical development of multi-specific, multi-valent agents for the company’s lead programs in immune-mediated diseases and oncology.
Dr. Greg Hughes
Codexis Appoints VP, Strategic Alliance and Product Development
Codexis, a developer of engineered enzymes for pharmaceutical, biofuel, and chemical production, has appointed Greg Hughes, Ph.D., as VP, strategic alliance and product development. Dr. Hughes spent the last 11 years in process chemistry at Merck with a primary focus in developing and implementing biocatalysis technology.
Dr. Rick Morgan
Bluebird Bio names VP of Immunotherapy
Bluebird Bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, has named Rick Morgan, Ph.D., as VP, immunotherapy.
Dr. Morgan joins the company from National Cancer Institute (NCI) at the National Institutes of Health where he was a staff scientist, working on genetically modified T-lymphocytes.
Dr. Jan Henrik ter Meulen
Immune Design Appoints Chief Scientific Officer
Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions has appointed Jan Henrik ter Meulen, M.D., as its chief scientific officer.
A veteran vaccine researcher in pharmaceutical, biotechnology and academic settings, Dr. ter Meulen brings more than two decades of immune-based research experience to Immune Design. He has previously led R&D efforts for multiple vaccine and antibody-based programs.
Dr. Pablo Jimenez
Celsus Therapeutics Appoints Chief Medical Officer
Celsus Therapeutics, an emerging growth, development-stage biopharmaceutical company, has appointed Pablo Jimenez, M.D., as chief medical officer. This appointment reflects Celsus’ continued growth as the company advances the development of its lead clinical asset, MRX-6, a non-steroidal anti-inflammatory cream for the treatment of eczema and other skin inflammatory disorders.
Dr. Jimenez has served more than two decades as a successful senior pharmaceutical executive in clinical development and medical affairs within the dermatology, wound healing, respiratory, and oncology therapeutic areas
Dr. Jyrki Mattila
iCeutica Appoints Chief Business Officer
iCeutica, which is creating branded medicines that provide meaningful clinical benefits to patients, physicians, and payers, has named Jyrki Mattila, M.D., Ph.D., chief business officer.
Dr. Mattila brings more than 25 years of business development and management experience to iCeutica and has negotiated and closed more than 50 business agreements, including in- and out-licensing, co-marketing, collaboration and product acquisition arrangements.
Medac Names President and CEO
Medac Pharma, a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, has named Terri Shoemaker as president and CEO.
Previously, Ms. Shoemaker served as VP of sales at InterMune, where she developed a large-scale commercial sales infrastructure in preparation for the launch of a treatment for idiopathic pulmonary fibrosis.
Comprehend Expands Executive Team
Comprehend has named life-sciences and technology veterans Lee Black and Ben McGraw to its executive team to support growth in adoption of its cloud-based clinical data insights software. Mr. Black and Mr. McGraw are charged with leading the company’s sales and marketing strategy targeting pharmaceutical, biotech, medical device companies, and contract research organizations.
Mr. Black, who serves as VP of sales, previously served as director of sales engineering at Meraki, which was sold to Cisco Systems in 2013. Mr. McGraw, VP of marketing, previously served as director of life science industry solutions at TIBCO Software.
Roska Healthcare Expands Client Services Team Roska Healthcare Advertising has made four recent hires: Joe Baker as account executive; Michele Hackett as senior account director; Alicia Wright as senior project manager; and Michele Linder-Moldover as senior campaign operations manager.
Mr. Baker comes to Roska from Complete Healthcare Communications, where he worked as a medical publications project coordinator for a global vaccine franchise. At Roska, he manages client activities related to current and upcoming projects, as well as provide forecasting and budgeting of financials.
Ms. Linder-Moldover joins Roska following four years as a database marketing account supervisor at Harte-Hanks, where she managed CRM campaigns for multiple Eli Lilly brands.
Ms. Hackett, a Roska alum, returns after stints at Novo Nordisk and Genentech. Her efforts support the over-active bladder franchise of one of the agency’s key accounts, as well as provide strategic direction for the franchise’s CRM initiative.
Ms. Wright comes to Roska following more than eight years at Discovery USA (formerly Saatchi & Saatchi Science). At Roska, she provides project management for one of the firm’s agency-of-record relationships.
Ogilvy CommonHealth Worldwide Promotes Two
Ogilvy CommonHealth Worldwide, the health behavior experts of Ogilvy & Mather, has promoted two seasoned professionals within the organization’s payer marketing groups.
Amber Gilbert has been promoted from chief strategy officer to executive VP, director of client services, at Ogilvy CommonHealth Payer Marketing.
Richard Trezza has been promoted from executive VP, director of client services, to general manager of both Ogilvy CommonHealth Payer Marketing and Ogilvy Healthworld Payer Marketing. In his new role, Mr. Trezza will oversee the strategic planning, new business initiatives and day-to-day management of both agencies.